Skip to main content
Premium Trial:

Request an Annual Quote

OncoMethylome Expands MGMT Methylation Agreement with Schering-Plough

NEW YORK (GenomeWeb News) - OncoMethylome Sciences said yesterday that it has extended an existing agreement with Schering-Plough to provide methylation testing in clinical trials focused on brain cancer and other cancers.
 
The agreement applies to OncoMethylome’s methylation assay for the MGMT biomarker, which has been shown to be methylated in a number of cancer types.
 
The company currently provides its MGMT methylation service for Schering-Plough for a multi-center clinical trial that is evaluating whether brain tumor patients can benefit from a more intensive temozolomide drug treatment regimen.
 
Under the terms of the new agreement, OncoMethylome’s assay will be used for MGMT methylation testing in “multiple national and international clinical trials” involving temozolomide in brain cancer and other cancers, the company said.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.